调节性T细胞在动脉粥样硬化发生机制中作用的研究进展  

Research progress of regulatory T cells in the pathogenesis of atherosclerosis

作　　者：谭强[1] 郑国学 郑江华[1] TAN Qiang;ZHENG Guoxue;ZHENG Jianghua(Department of Vascular Surgery,Affiliated Hospital of North Sichuan Medical College,Nanchong,Sichuan 637000,China)

机构地区：[1]川北医学院附属医院血管外科,四川省南充市637000

出　　处：《中国动脉硬化杂志》2020年第9期823-828,共6页Chinese Journal of Arteriosclerosis

基　　金：四川省卫生厅基金项目(10035);川北医学院附属医院院内基金项目(2020ZD012)。

摘　　要：动脉粥样硬化(As)是动脉血管壁的一种慢性炎症性病变,相关免疫机制参与其发生、发展过程。调节性T细胞(Treg)是一种具有独特免疫调节功能的T淋巴细胞亚群,大量证据表明,Treg的数量变化和功能障碍与As的发病机制密切相关。文章简要阐述Treg在As发展中的作用机制,并介绍了Treg作为一种新型药物治疗靶点在预防和治疗As中的最新研究进展,以期对动脉粥样硬化性疾病的发生与防治提供新思路。Chronic inflammation plays an important role in the development of atherosclerosis(As).Immune response related mechanisms are involved in the process of arterial inflammatory disease.Regulatory T cell(T regulatory cells,Treg)is a T lymphocyte subset with unique immunomodulatory function.A great deal of evidence shows that the quantitative changes and dysfunction of Treg are closely related to the pathogenesis of As.This paper briefly describes and summarizes the mechanism of Treg in the development of As,and introduces the latest research progress of Treg as a new drug therapeutic target in the prevention and treatment of As,in order to provide new ideas for the prevention and treatment of atherosclerotic diseases.

关 键 词：调节性T细胞 动脉粥样硬化 发病机制 免疫调节 治疗策略 

分 类 号：R5[医药卫生—内科学]